港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

宝济药业-B

67.000

+1.0501.59%

成交量：54.84万

成交额：3,705.05万

市值：218.41亿

市盈率：- -

高：69.200

开：65.950

低：65.800

收：65.950

52周最高：70.000

52周最低：56.000

股本：3.26亿

香港流通股本：1.54亿

量比：0.19

换手率：0.36%

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：22.19

市盈率(LYR):- -

市销率: 423.15

数据加载中...

总览公司新闻资讯公告

宝济药业-B12月16日主力净流入155.4万元散户资金抛售

宝济药业-B12月15日主力净流出15.6万元散户资金买入

山东新动能基金公司又一投资企业在港交所上市

宝济药业挂牌港交所，山东国资多点加码生物医药

交银国际作为联席全球协调人助力宝济药业完成港股IPO项目

宝济药业-B12月11日主力净流入566.1万元散户资金抛售

康方生物双抗药物启动II期临床，适应证为中国人高发的食管鳞癌；宝济药业登陆港交所，上半年净亏损扩大 | 掘金创新药

每日经济新闻

星瞰IPO | 宝济药业再创造富神话，基石投资者日赚1.55亿港元

异动解读 | 宝济药业-B(02659)盘中大涨5.08%，三驾马车战略与IPO热潮驱动股价飙升

“自我造血”的新晋18A，宝济药业-B(02659)以“三驾马车”打造可持续增长样本

首日暴涨130%！持续亏损的它能否跑通从"技术卡位"到"商业造血"？

安科生物以基石投资赋能，宝济药业成功挂牌港交所主板

宝济药业正式登陆港交所，开盘大涨129%，旗下三大核心产品即将商业化

独角兽早知道

宝济药业-B(02659)捐款100万港元驰援香港大埔火灾全力支持救灾重建工作

异动解读 | 新股宝济药业-B(02659)首日盘中飙涨120.81%，公开发售超购3526倍引爆市场热情

上海宝济药业-B在香港首日以每股60.5港元开盘，较发行价每股26.38港元大幅上涨

港股开盘 | 恒指平开，科指低开0.04%！宝济药业-B首挂飙涨近130%

老虎资讯综合

宝济药业-B(02659.HK)香港IPO发行价定为每股26.38港元净筹9.2亿港元

沸腾！暗盘，暴涨超113%！

老虎暗盘 | 宝济药业-B涨超100%，中签一手赚超2700港元

老虎资讯综合

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/02659/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02659","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02659\",,,,,undefined,":{"symbol":"02659","market":"HK","secType":"STK","nameCN":"宝济药业-B","latestPrice":67,"timestamp":1765872498445,"preClose":65.95,"halted":0,"volume":548446,"delay":0,"floatShares":154000000,"shares":325981465,"eps":0,"marketStatus":"已收盘","change":1.05,"latestTime":"12-16 16:08:18","open":65.95,"high":69.2,"low":65.8,"amount":37050529,"amplitude":0.051554,"askPrice":67.05,"askSize":2300,"bidPrice":67,"bidSize":600,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765935000000},"marketStatusCode":5,"adr":0,"listingDate":1765296000000,"exchange":"SEHK","adjPreClose":65.95,"openAndCloseTimeList":[[1765848600000,1765857600000],[1765861200000,1765872000000]],"volumeRatio":0.186749,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02659\",,,,,undefined,":{"symbol":"02659","floatShares":154000000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.186749,"shares":325981465,"dividePrice":0,"high":69.2,"amplitude":0.051554,"preClose":65.95,"low":65.8,"week52Low":56,"pbRate":"22.19","psRate":"423.15","week52High":70,"institutionHeld":0,"latestPrice":67,"committee":-0.586207,"eps":0,"divideRate":0,"volume":548446,"delay":0,"ttmEps":0,"open":65.95,"prevYearClose":26.38,"prevWeekClose":68.35,"prevMonthClose":26.38,"prevQuarterClose":26.38,"fiveDayClose":26.38,"twentyDayClose":26.38,"sixtyDayClose":26.38},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02659\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02659\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02659\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02659\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02659","date":"2025-12-15","current":-51.198713,"percent":0.5,"low":-53.651638,"twenty":-53.247307,"median":-51.198713,"eighty":-43.327204,"high":-20.527356,"avg":-45.510219,"sd":12.597322,"marketCap":21498477616},"quantilePoints":[{"date":"2025-12-12","current":-53.146224,"twenty":-53.348389,"median":-51.086695,"eighty":-37.627242,"marketCap":22280833132},{"date":"2025-12-15","current":-51.198713,"twenty":-53.247307,"median":-51.198713,"eighty":-43.327204,"marketCap":21498477616}],"updateTime":1765862230521},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02659\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2591026826","title":"宝济药业-B12月16日主力净流入155.4万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2591026826","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591026826?lang=zh_cn&edition=fundamental","pubTime":"2025-12-16 16:16","pubTimestamp":1765872960,"startTime":"0","endTime":"0","summary":"12月16日, 宝济药业-B股价涨1.59%，报收67.00元，成交金额3705.1万元，换手率0.36%，振幅5.16%，量比0.00。宝济药业-B今日主力资金净流入155.4万元，上一交易日主力净流出15.6万元。该股近5个交易日上涨153.98%，主力资金累计净流入719.1万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入719.1万元，其中净流入天数为3日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216162249a4519163&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216162249a4519163&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02659"],"gpt_icon":1},{"id":"2591616778","title":"宝济药业-B12月15日主力净流出15.6万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2591616778","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591616778?lang=zh_cn&edition=fundamental","pubTime":"2025-12-15 16:15","pubTimestamp":1765786536,"startTime":"0","endTime":"0","summary":"12月15日, 宝济药业-B股价跌3.51%，报收65.95元，成交金额5059.6万元，换手率0.50%，振幅6.14%，量比0.00。宝济药业-B今日主力资金净流出15.6万元，上一交易日主力净流入13.1万元。该股近5个交易日上涨148.67%，主力资金累计净流入563.7万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入563.7万元，其中净流入天数为2日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215161815a44d2d53&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215161815a44d2d53&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02659"],"gpt_icon":0},{"id":"2591682812","title":"山东新动能基金公司又一投资企业在港交所上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2591682812","media":"国企研究","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591682812?lang=zh_cn&edition=fundamental","pubTime":"2025-12-13 06:30","pubTimestamp":1765578645,"startTime":"0","endTime":"0","summary":"12月10日，新动能基金公司投资企业上海宝济药业在香港联合交易所主板挂牌上市，发行价26.38港元，首日股价暴涨139%，市值突破205亿港元，成为2025年港股第23家上市的医药企业，也成为公司收获的第116家投资上市企业。新动能基金公司于2021年通过山东新旧动能转换基金对宝济药业进行投资，助力企业打通研发、临床与产业化路径，持续陪伴企业穿越创新周期，最终走向资本市场。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213063608a69cc39c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213063608a69cc39c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02659"],"gpt_icon":0},{"id":"2590504723","title":"宝济药业挂牌港交所，山东国资多点加码生物医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2590504723","media":"大众日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590504723?lang=zh_cn&edition=fundamental","pubTime":"2025-12-12 22:01","pubTimestamp":1765548074,"startTime":"0","endTime":"0","summary":"宝济药业在招股书中解释称，“绝大部分的净亏损主要产生自研发开支及行政开支”。尽管尚未盈利、研发投入高企，宝济药业仍受到资本市场关注，并获得山东资本的多轮支持，亦折射出山东国资在创新生物医药赛道的持续布局。从宝济药业招股书披露的IPO前投资者名单来看，山东本地国有资本的身影清晰可见。山东财欣也称，其于2021年及2024年通过基金对宝济药业进行了两轮投资。此次宝济药业上市，成为财欣投资公司累计收获的第五个IPO项目。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212220329a44516ed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212220329a44516ed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02659"],"gpt_icon":1},{"id":"2590519099","title":"交银国际作为联席全球协调人助力宝济药业完成港股IPO项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2590519099","media":"交银国际","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590519099?lang=zh_cn&edition=fundamental","pubTime":"2025-12-11 21:41","pubTimestamp":1765460485,"startTime":"0","endTime":"0","summary":"宝济药业本次全球发售定价每股26.38港元，发行37,911,700股H股，融资规模约为10.00亿港元。交银国际担任联席全球协调人、联席账簿管理人兼联席牵头经办人，全程高效助力宝济药业顺利登陆港股资本市场。宝济药业已布局多个治疗领域的自主管线，拥有12款自主开发的在研和上市产品。通过将稳健的生产体系与前瞻性的研发能力深度融合，宝济药业已形成“创新研发—生物制造—临床转化”一体化的全产业链布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211214729a699b2f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211214729a699b2f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03329","BK1147","02659"],"gpt_icon":1},{"id":"2590659546","title":"宝济药业-B12月11日主力净流入566.1万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2590659546","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590659546?lang=zh_cn&edition=fundamental","pubTime":"2025-12-11 16:15","pubTimestamp":1765440949,"startTime":"0","endTime":"0","summary":"12月11日, 宝济药业-B股价涨9.52%，报收69.00元，成交金额1.4亿元，换手率1.43%，振幅13.10%，量比0.00。该股近5个交易日上涨165.35%，主力资金累计净流入566.1万元；近20日主力资金累计净流入566.1万元，其中净流入天数为1日。该股主力净额占比0.05%，港股市场排名89/2692。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211162037a441f3a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211162037a441f3a4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02659"],"gpt_icon":0},{"id":"2590598715","title":"康方生物双抗药物启动II期临床，适应证为中国人高发的食管鳞癌；宝济药业登陆港交所，上半年净亏损扩大 | 掘金创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2590598715","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590598715?lang=zh_cn&edition=fundamental","pubTime":"2025-12-11 15:51","pubTimestamp":1765439499,"startTime":"0","endTime":"0","summary":"目前，宝济药业共有12款自主研发产品。前沿洞察康方生物双抗药物卡度尼利单抗启动II期临床，适应证为中国人高发的食管鳞癌药物临床试验登记与信息公示平台数据显示，康方生物的围手术期卡度尼利单抗联合新辅助化疗治疗可切除食管鳞癌的多中心、随机、对照II期临床试验已启动，首次公示信息日期为2025年12月2日。目前，食管癌的主要治疗方式仍然是手术、化疗和放疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211155232a441e332&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211155232a441e332&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0348766576.USD","LU0417516902.SGD","09926","IE00B5MMRT66.SGD","LU0348767384.USD","LU0417516571.SGD","BK1161","LU0634319403.HKD","LU2476274308.USD","LU0540923850.HKD","IE00B543WZ88.USD","LU0348825331.USD","LU0348783233.USD","LU1794554557.SGD","06978","LU0561508036.HKD","LU1961090484.USD","IE00BPRC5H50.USD","LU2399975544.HKD","00512","LU2476274720.SGD","LU1720050803.USD","LU2488822045.USD","LU2778985437.USD","02659","LU0417516738.SGD","BK1574","LU0348784397.USD","LU0348735423.USD","LU0348827113.USD"],"gpt_icon":1},{"id":"2590222561","title":"星瞰IPO | 宝济药业再创造富神话，基石投资者日赚1.55亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590222561","media":"星岛产研","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590222561?lang=zh_cn&edition=fundamental","pubTime":"2025-12-11 11:45","pubTimestamp":1765424745,"startTime":"0","endTime":"0","summary":"翻倍的股价下，宝济药业股东及基石投资者手中的股份也水涨船高，甚至日赚上亿元。于前一晚的暗盘交易阶段，宝济药业已大涨逾110%，总市值破180亿港元。按当日收盘价计算，宝济药业翻倍的股价也令上述三家基石投资者上市首日账上浮盈累计达到2.78亿港元，其中持有424.56万股的安科生物，单日浮盈便达1.55亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211133149a441a0d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211133149a441a0d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02659"],"gpt_icon":1},{"id":"1100856862","title":"异动解读 | 宝济药业-B(02659)盘中大涨5.08%，三驾马车战略与IPO热潮驱动股价飙升","url":"https://stock-news.laohu8.com/highlight/detail?id=1100856862","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100856862?lang=zh_cn&edition=fundamental","pubTime":"2025-12-11 09:38","pubTimestamp":1765417124,"startTime":"0","endTime":"0","summary":"12月11日，港股生物科技板块新秀宝济药业-B盘中大涨5.08%，引发市场关注。消息面上，宝济药业凭借独特的“三驾马车”战略实现差异化竞争：其一是聚焦临床场景变革而非靶点红海的战略定位；其二是以合成生物学为核心的先进生物制造技术壁垒；其三是自建产能带来的总成本领先优势。此外，公司于12月10日登陆港交所首日即暴涨138.8%，市值突破205亿港元，反映出投资者对其商业化能力的认可。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"gpt_icon":0},{"id":"2590557916","title":"“自我造血”的新晋18A，宝济药业-B(02659)以“三驾马车”打造可持续增长样本","url":"https://stock-news.laohu8.com/highlight/detail?id=2590557916","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590557916?lang=zh_cn&edition=fundamental","pubTime":"2025-12-11 09:08","pubTimestamp":1765415296,"startTime":"0","endTime":"0","summary":"在这一背景下，宝济药业-B凭借与众不同的三驾“马车”，开辟了一条独特的差异化赛道，为行业提供了一种全新的Biotech生存逻辑与创新范式。这种由技术升级带来的高质量和高安全性，正是宝济药业在市场上实现“技术替代”红利的核心保障。目前，宝济药业已建成和在建的生产基地总占地面积近10万平方米，预计反应器总容积将达到约26,100L，年产能预计可达2250万份制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380193.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659"],"gpt_icon":1},{"id":"2590307091","title":"首日暴涨130%！持续亏损的它能否跑通从\"技术卡位\"到\"商业造血\"？","url":"https://stock-news.laohu8.com/highlight/detail?id=2590307091","media":"抗体圈","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590307091?lang=zh_cn&edition=fundamental","pubTime":"2025-12-10 14:44","pubTimestamp":1765349040,"startTime":"0","endTime":"0","summary":"从行业现状来看，全球自身免疫性疾病药物市场规模已突破千亿美元，其中生物制剂占比持续提升。国内方面，随着居民健康意识提升与诊断技术进步，自身免疫性疾病确诊率逐年攀升，而国产创新药物供给相对不足，大量市场份额被进口药物占据。KJ103目前处于III期开发阶段用于治疗肾脏移植前脱敏及病理性IgG介导自身免疫性疾病。多款产品处于在研阶段，宝济药业存在持续的研发投入与亏损。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210164946a43fa8a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210164946a43fa8a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02659"],"gpt_icon":1},{"id":"2590882585","title":"安科生物以基石投资赋能，宝济药业成功挂牌港交所主板","url":"https://stock-news.laohu8.com/highlight/detail?id=2590882585","media":"安科生物","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590882585?lang=zh_cn&edition=fundamental","pubTime":"2025-12-10 14:27","pubTimestamp":1765348074,"startTime":"0","endTime":"0","summary":"2025年12月10日，安徽安科生物工程（集团）股份有限公司作为基石投资者参股的上海宝济药业股份有限公司正式在香港联合交易所主板挂牌上市，股份代码：2659HK。安科生物不仅是宝济药业此次IPO的关键基石投资者，更是其重要的商业合作伙伴。晟诺娃作为宝济药业的核心创新成果，已于2025年8月获批上市。往期回顾安科生物1.12亿港元基石投资宝济药业港股IPO，深化辅助生殖领域协同合作长效FSH晟诺娃学术研讨会“晟启新篇”在合肥成功举办","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210170055a72f5fd1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210170055a72f5fd1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02659"],"gpt_icon":1},{"id":"2590683374","title":"宝济药业正式登陆港交所，开盘大涨129%，旗下三大核心产品即将商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2590683374","media":"独角兽早知道","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590683374?lang=zh_cn&edition=fundamental","pubTime":"2025-12-10 10:42","pubTimestamp":1765334576,"startTime":"0","endTime":"0","summary":"集团的管线主要包括12款自主开发在研产品，包括三款核心产品、四款其他临床阶段候选药物及五款临床前资产。今日开盘，宝济药业涨129.34%，报60.50港元/股，市值197.22亿港元。随着公司正式登陆资本市场，在充裕资金与清晰战略的双重驱动下，宝济药业有望加速推进核心产品的商业化进程，将技术优势转化为实实在在的业绩增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512101048219534b013&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512101048219534b013&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02659"],"gpt_icon":1},{"id":"2590393379","title":"宝济药业-B(02659)捐款100万港元驰援香港大埔火灾 全力支持救灾重建工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2590393379","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590393379?lang=zh_cn&edition=fundamental","pubTime":"2025-12-10 09:46","pubTimestamp":1765331195,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，11月26日，香港大埔宏福苑多栋住宅楼发生火灾，造成重大人员伤亡，灾情牵动着社会各界的心。值此艰难时刻，为帮助受灾同胞渡过难关，宝济药业-B(02659)积极履行企业社会责任，宣布捐款100万港元，用于受灾居民的紧急救援、生活物资补给、医疗救助及后续重建工作。宝济药业向遇难者及其家属表示沉痛哀悼，并向所有奋不顾身投入救援的消防及救护人员，以及第一时间响应的前线团队致以崇高敬意，感谢他们在危难关头展现的专业精神与无私付出。宝济药业将继续密切关注救灾进展，期盼在社会各界同心同力的援助下，社区早日恢复秩序，市民重归平安生活。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379689.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659"],"gpt_icon":0},{"id":"1175227784","title":"异动解读 | 新股宝济药业-B(02659)首日盘中飙涨120.81%，公开发售超购3526倍引爆市场热情","url":"https://stock-news.laohu8.com/highlight/detail?id=1175227784","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175227784?lang=zh_cn&edition=fundamental","pubTime":"2025-12-10 09:33","pubTimestamp":1765330391,"startTime":"0","endTime":"0","summary":"宝济药业-B今日盘中大涨120.81%，创下港股新股首日交易的亮眼表现。消息面上，宝济药业-B此次IPO获得市场狂热追捧，香港公开发售部分超额认购达3526.34倍，国际配售部分也获6.59倍认购。宝济药业是一家临床及商业化阶段的生物技术公司，专注于合成生物技术开发重组生物药物。公司2025年上半年收入同比大增2716%，展现出强劲的商业化潜力。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"0f289a0c0f19ee2212a31014a11a9f2a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"gpt_icon":0},{"id":"1167510070","title":"上海宝济药业-B在香港首日以每股60.5港元开盘，较发行价每股26.38港元大幅上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=1167510070","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167510070?lang=zh_cn&edition=fundamental","pubTime":"2025-12-10 09:22","pubTimestamp":1765329779,"startTime":"0","endTime":"0","summary":"上海宝济药业-B在香港首日的开盘价定为每股60.5港元，相较于发行价每股26.38港元大幅上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"0f289a0c0f19ee2212a31014a11a9f2a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"gpt_icon":0},{"id":"1170105562","title":"港股开盘 | 恒指平开，科指低开0.04%！宝济药业-B首挂飙涨近130%","url":"https://stock-news.laohu8.com/highlight/detail?id=1170105562","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170105562?lang=zh_cn&edition=fundamental","pubTime":"2025-12-10 09:20","pubTimestamp":1765329630,"startTime":"0","endTime":"0","summary":"12月10日，恒生指数开盘上涨1.26点，涨幅0.0%，报25435.49点；恒生科技指数开盘下跌2.33点，跌幅0.04%，报5552.35点；国企指数开盘上涨0.46点，涨幅0.01%，报8936.87点；红筹指数开盘上涨14.33点，涨幅0.35%，报4144.82点。贵金属板块普涨，中国白银集团涨超7%，赤峰黄金涨近2%，招金矿业、、山东黄金、紫金黄金国际涨超1%；长飞光纤光缆跌超3%，拟折让约14.93%配售合共7000万股配售股份，净筹约22.29亿港元；宝济药业-B首挂飙涨近130%，此前公开发售获得3526.34倍认购，一手中签率7%。","market":"hk","thumbnail":"https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"0f289a0c0f19ee2212a31014a11a9f2a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSTECH","02659","HSI"],"gpt_icon":0},{"id":"2590344140","title":"宝济药业-B(02659.HK)香港IPO发行价定为每股26.38港元 净筹9.2亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590344140","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590344140?lang=zh_cn&edition=fundamental","pubTime":"2025-12-09 22:09","pubTimestamp":1765289380,"startTime":"0","endTime":"0","summary":"格隆汇12月9日丨宝济药业-B公告，公司全球发售37,911,700股H股，每股H股26.38港元，所得款项净额9.2亿港元。香港公开发售股份数目占全球发售股份数目10%，获认购3,526.34倍；国际发售股份数目占全球发售股份90%，获认购6.59倍。假设全球发售于2025年12月10日(星期三)上午八时正或前成为无条件，预期H股将于2025年12月10日(星期三)上午九时正开始在联交所买卖。H股将以100股H股为一手买卖单位进行交易，H股的股份代号为2659。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2025/12/09220954656574.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02659"],"gpt_icon":0},{"id":"2590234961","title":"沸腾！暗盘，暴涨超113%！","url":"https://stock-news.laohu8.com/highlight/detail?id=2590234961","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590234961?lang=zh_cn&edition=fundamental","pubTime":"2025-12-09 20:58","pubTimestamp":1765285080,"startTime":"0","endTime":"0","summary":"　　今日，港股新股宝济药业-B股价在暗盘交易中一度暴涨超115%，以每手100股计算，若不计手续费，每手可赚3057港元。　　据悉，宝济药业-B于12月2日至5日招股，市场统计数据显示，截至12月5日，宝济药业-B获券商借出2692.1亿港元孖展，以公开发售集资额1亿港元计算，超购2690.8倍。　　12月9日，宝济药业-B股价在暗盘交易中表现强劲，一度暴涨超115%，截至暗盘收盘，报56港元，较招股价大涨112.28%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/zqgd/2025-12-09/doc-inhaffac0778007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02659"],"gpt_icon":1},{"id":"1102812015","title":"老虎暗盘 | 宝济药业-B涨超100%，中签一手赚超2700港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1102812015","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102812015?lang=zh_cn&edition=fundamental","pubTime":"2025-12-09 16:15","pubTimestamp":1765268153,"startTime":"0","endTime":"0","summary":"12月9日，宝济药业-B暗盘涨超100%，总市值超176亿港元。宝济药业的药物开发专注于高效优化具有重大市场价值或未开发商机的经验证疗法，这使公司在生物制药行业脱颖而出。通过升级已在临床实现广泛采用的现有疗法，宝济药业确保公司的创新可直接造福既有及不断扩大的患者群体。宝济药业的产品管线旨在通过公司的合成生物技术能力，着力攻克该等产品的关键限制，将开发重点与真实的临床需求紧密联系。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"0f289a0c0f19ee2212a31014a11a9f2a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":39,"code":"91000000","status":"200"}]}}